Lasix for the Prevention of De Novo Postpartum Hypertension: A Randomized Controlled Trial (LAPP Trial)

Who is this study for? Patients with Postpartum Preeclampsia
What treatments are being studied? Furosemide
Status: Completed
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Primary objective: To evaluate whether oral furosemide can help prevent de novo postpartum hypertension (new-onset high blood pressure after delivery) by reducing blood pressure after delivery in high-risk women. Secondary objectives: To evaluate whether oral furosemide administered to high-risk women after delivery can reduce the frequency of postpartum hypertensive episodes, the need for antihypertensive therapy, the risk of postpartum preeclampsia, and the incidence of severe maternal morbidity.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Postpartum women

• No antenatal diagnosis of hypertensive disorder of pregnancy at the time of admission for delivery, defined as existing chronic hypertension diagnosis or documented blood pressure of ≥140 systolic OR ≥90 diastolic on at least 2 occasions at least 4 hours apart prior to delivery admission who do not go on to get magnesium for seizure prophylaxis by the time of delivery

• At least 18 years of age

• English or Spanish speakers

• One or more high risk factors for development of de novo postpartum hypertension

Locations
United States
New York
Columbia University Irving Medical Center
New York
Time Frame
Start Date: 2021-10-20
Completion Date: 2022-05-28
Participants
Target number of participants: 82
Treatments
Experimental: Lasix (furosemide)
Furosemide 20 mg, oral, once daily for 5 days
Placebo_comparator: Placebo
Identical-appearing placebo, oral, once daily for 5 days
Authors
Related Therapeutic Areas
Sponsors
Leads: Columbia University

This content was sourced from clinicaltrials.gov